TORONTO, Aug. 28, 2007 (PRIME NEWSWIRE) -- Cannasat Therapeutics Inc. (TSX-V:CTH), the developer of novel cannabinoid-based pharmaceutical products, today announced its results for the six months ended June 30, 2007. Cannasat also reports that activities over this period have led to approval from Health Canada to commence its first Phase 1 clinical study with its lead product, CAT 310, for patients with neuropathic pain. The study is expected to be completed in Q4 2007 and represents a major milestone for the Company.
